drugset / Trial / NCT00971581

Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole

NCT00971581

Phase 3 Completed 52 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary Objective: To confirm the safety and tolerability of the fixed dose combination of a Non-Steroidal Anti-Inflammatory Drug (NSAID), ketoprofen, associated to a Proton Pump Inhibitor (PPI), omeprazole, in Mexican patients. Secondary Objective: To confirm the efficacy of the combination: * Relief of pain (Visual Analyzed Score (VAS)) * Patients global assessment of disease activity, scored as a scale of 1 (no limitation of normal activities) to 5 (inability to carried out all normal activities)

Timeline

Start
2009-08
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoprofen Small molecule 200 mg
Subject Omeprazole Other / unclassified 20 mg

Indications

No indication recorded.